FAK Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
FAK Inhibitor 14 | 4506-66-5 | sc-203950 sc-203950A | 10 mg 50 mg | $107.00 $233.00 | 86 | |
FAK Inhibitor 14 is a selective small molecule that targets focal adhesion kinase (FAK), disrupting its autophosphorylation and downstream signaling. By interfering with the interaction between FAK and its binding partners, it alters cellular adhesion and migration dynamics. This compound exhibits unique kinetics, demonstrating a rapid onset of action and prolonged effects on cellular pathways, influencing processes such as cytoskeletal rearrangement and cell survival. Its specificity for FAK over other kinases highlights its potential for nuanced modulation of cellular behavior. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Inhibits BCR-ABL and c-KIT tyrosine kinases by binding to the ATP-binding site, preventing phosphorylation and downstream signaling. | ||||||
Masitinib | 790299-79-5 | sc-211777 | 10 mg | $180.00 | ||
Masitinib is a selective inhibitor of focal adhesion kinase (FAK) that modulates cellular signaling by disrupting FAK's interactions with integrins and other signaling molecules. This compound exhibits unique binding kinetics, allowing for a rapid engagement with the FAK active site, which leads to a significant alteration in cellular adhesion properties. Its ability to selectively target FAK enhances its role in influencing cellular motility and structural integrity, making it a distinct player in cellular dynamics. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Targets EGFR tyrosine kinase, potentially blocking intracellular signaling pathways involved in cell proliferation and survival. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Inhibits multiple receptor tyrosine kinases including VEGFR and PDGFR, impeding angiogenesis and tumor growth. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $306.00 $465.00 $1102.00 | 3 | |
PF-562271 is a potent inhibitor of focal adhesion kinase (FAK) that selectively disrupts its autophosphorylation and downstream signaling pathways. This compound exhibits a unique mechanism of action by stabilizing the inactive conformation of FAK, thereby preventing its interaction with key substrates. Its distinct binding affinity alters the phosphorylation state of various proteins, influencing cytoskeletal organization and cell migration dynamics. The compound's specificity for FAK over other kinases underscores its role in modulating cellular responses to environmental cues. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Targets BCR-ABL and SRC family kinases, potentially preventing phosphorylation and inhibiting oncogenic signaling. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Targets EGFR and HER2 tyrosine kinases, potentially blocking downstream signaling pathways involved in cell growth and survival. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Binds to the ATP-binding site of EGFR, potentially disrupting downstream signaling pathways in cancer cells. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Inhibits VEGFR, PDGFR, and c-KIT, potentially impeding angiogenesis and tumor growth by disrupting receptor signaling. | ||||||